경구 단백질 및 펩타이드 시장 : 규모, 점유율, 성장, 업계 분석, 지역별 동향 및 예측(2026-2034년)

Oral Proteins and Peptides Market Size, Share, Growth and Industry Outlook (2025-2034)

The global oral proteins and peptides market was valued at USD 3.36 billion in 2025 and is projected to grow from USD 3.97 billion in 2026 to USD 9.17 billion by 2034, registering a CAGR of 11.03% during the forecast period. North America dominated the market with a 71.72% share in 2025, supported by the strong commercialization of oral peptide therapies, advanced healthcare infrastructure, and high adoption of innovative biologics.

Oral proteins and peptides represent a major advancement in drug delivery, enabling protein- and peptide-based therapies to be administered through tablets or capsules rather than injections. These therapies improve patient convenience, increase treatment adherence, and support earlier intervention in chronic disease management. The market is being driven by the commercial success of oral semaglutide, increasing physician acceptance of oral peptide therapies, growing investments in oral drug delivery technologies, and expanding development pipelines for oral insulin, oral PTH analogs, GLP-2 therapies, and obesity treatments.

Market Size and Forecast

• 2025 Market Size: USD 3.36 Billion
• 2026 Market Size: USD 3.97 Billion
• 2034 Market Size: USD 9.17 Billion
• CAGR (2026-2034): 11.03%

The increasing prevalence of diabetes, obesity, endocrine disorders, and metabolic diseases is expected to create sustained demand for oral peptide therapeutics throughout the forecast period.

Key Market Trends

Rising Preference for Non-Invasive Therapies

One of the most significant trends shaping the market is the growing preference for non-invasive treatment options. Patients increasingly favor oral medications over injectable therapies due to greater convenience, reduced needle anxiety, and improved adherence.

The approval of oral GLP-1 therapies has demonstrated strong commercial potential for oral biologics. In December 2025, Novo Nordisk received FDA approval for the Wegovy pill, further strengthening confidence in oral peptide-based weight management therapies.

Market Drivers

Increasing Prevalence of Chronic Diseases

The growing burden of chronic diseases continues to drive demand for oral proteins and peptides. Conditions such as type 2 diabetes, obesity, osteoporosis, and endocrine disorders require long-term treatment, making oral therapies highly attractive for both patients and healthcare providers.

According to WHO data, approximately 16% of adults globally were living with obesity in 2022. The expanding patient population creates significant opportunities for oral peptide therapies that offer efficacy comparable to injectable alternatives.

Growing Adoption of Oral GLP-1 Therapies

Commercial success of oral semaglutide products has encouraged pharmaceutical companies to invest heavily in next-generation oral biologics. Increasing physician confidence and patient acceptance are accelerating market expansion worldwide.

Market Restraints

High Development Costs

Developing oral peptide therapies remains expensive due to formulation complexity, absorption enhancement technologies, extensive clinical studies, and specialized manufacturing requirements. These factors increase development risks and create barriers for smaller biotechnology companies.

Low Bioavailability Challenges

Proteins and peptides are vulnerable to degradation within the gastrointestinal tract, making systemic absorption difficult. Ensuring consistent bioavailability remains one of the biggest scientific challenges for manufacturers.

Market Opportunities

Advances in Oral Drug Delivery Technologies

Innovations in absorption enhancers, protective coatings, and tablet delivery platforms are opening new growth opportunities. These technologies are enabling more biologics to be developed as oral formulations, expanding applications beyond diabetes into osteoporosis, obesity, and endocrine disorders.

In March 2026, Entera Bio submitted a streamlined Phase III protocol for its oral osteoporosis therapy EB613, highlighting the growing maturity of oral peptide delivery technologies.

Segment Analysis

By Drug Class

The GLP-1 Peptides segment dominated the market in 2025 due to strong commercial adoption and growing use in diabetes and obesity management. Novo Nordisk reported USD 3.4 billion in Rybelsus sales during 2025, reinforcing the segment's leadership.

The PTH Analogs segment is projected to record the fastest growth during the forecast period owing to promising osteoporosis treatment pipelines.

By Therapeutic Area

The Metabolic Disorders segment held the largest market share in 2025, driven by rising diabetes and obesity prevalence and increasing use of oral semaglutide therapies.

By Age Group

The Adult segment dominated the market as currently approved oral peptide therapies primarily target adult patients suffering from chronic diseases requiring long-term treatment.

By Formulation

The Tablets segment accounted for the largest share in 2025 due to ease of administration, patient convenience, and widespread physician acceptance.

By Distribution Channel

Retail Pharmacies & Drug Stores led the market in 2025 and are expected to account for approximately 71.5% of market share in 2026, supported by broad product availability and repeat prescription demand.

Regional Analysis

North America

North America remained the largest regional market, valued at USD 2.41 billion in 2025. Strong reimbursement systems, early product commercialization, and rapid adoption of oral GLP-1 therapies support regional dominance.

The U.S. market is projected to reach approximately USD 2.62 billion in 2026, representing around 66% of global revenues.

Europe

Europe is expected to grow at a CAGR of 15.66%, driven by increasing adoption of oral semaglutide therapies and supportive reimbursement policies.

Asia Pacific

Asia Pacific is projected to reach USD 0.46 billion in 2026, supported by large diabetic populations, improving healthcare access, and growing demand for innovative metabolic therapies.

Latin America and Middle East & Africa

These regions are expected to witness gradual growth due to increasing awareness, expanding healthcare infrastructure, and rising prevalence of diabetes and obesity.

Competitive Landscape

The market remains highly concentrated, with major companies focusing on commercialization, strategic collaborations, and pipeline expansion.

Key Companies

• Novo Nordisk (Denmark)
• Chiesi Group (Italy)
• EnteraBio Ltd. (Israel)
• Oramed Pharmaceuticals (U.S.)
• Protagonist Therapeutics Inc. (U.S.)
• Biocon (India)
• Rani Therapeutics (U.S.)

Leading players are investing in oral GLP-1 therapies, oral insulin programs, oral PTH analogs, and advanced drug delivery technologies to strengthen their market positions.

Recent Industry Developments

• September 2025: EnteraBio reported positive pharmacokinetic data for its oral GLP-2 tablet.
• June 2025: Protagonist Therapeutics nominated PN-477 as an obesity-focused oral peptide candidate.
• February 2025: Rani Therapeutics announced positive preclinical oral semaglutide delivery data using RaniPill technology.
• November 2024: Protagonist reported positive Phase III results for oral peptide candidate icotrokinra.
• June 2024: Rani Therapeutics partnered with ProGen for development of RT-114 oral obesity treatment.

Conclusion

The oral proteins and peptides market is entering a transformative growth phase as pharmaceutical companies continue shifting biologic therapies from injectable formats to convenient oral formulations. Growing chronic disease prevalence, strong commercial performance of oral GLP-1 therapies, technological advancements in drug delivery, and expanding development pipelines are expected to drive market expansion from USD 3.36 billion in 2025 to USD 9.17 billion by 2034. While challenges related to bioavailability and development costs remain, continued innovation and regulatory support are expected to create substantial opportunities for manufacturers and investors over the coming years.

Segmentation By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Region

By Drug Class * GLP-1 Peptides

• Somatostatin Analogs
• PTH Analogs
• GLP-2 Peptides
• Others

By Therapeutic Area * Metabolic Disorders

• Endocrine Disorders
• Others

By Age Group * Pediatric

• Adult

By Formulation * Tablets

• Others

By Distribution Channel * Hospital Pharmacies

• Retail Pharmacies & Drug Stores
• Specialty Pharmacies & Others

By Region * North America (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Pipeline Analysis, By Key Players
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.3. New Product Launches, By Key Players
• 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. GLP-1 Peptides
  • 5.1.2. Somatostatin Analogs
  • 5.1.3. PTH Analogs
  • 5.1.4. GLP-2 Peptides
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 5.2.1. Metabolic Disorders
  • 5.2.2. Endocrine Disorders
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adult
• 5.4. Market Analysis, Insights and Forecast - By Formulation
  • 5.4.1. Tablets
  • 5.4.2. Others
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacies
  • 5.5.2. Retail Pharmacies & Drug Stores
  • 5.5.3. Specialty Pharmacies & Others
• 5.6. Market Analysis, Insights and Forecast - Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. GLP-1 Peptides
  • 6.1.2. Somatostatin Analogs
  • 6.1.3. PTH Analogs
  • 6.1.4. GLP-2 Peptides
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 6.2.1. Metabolic Disorders
  • 6.2.2. Endocrine Disorders
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adult
• 6.4. Market Analysis, Insights and Forecast - By Formulation
  • 6.4.1. Tablets
  • 6.4.2. Others
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital Pharmacies
  • 6.5.2. Retail Pharmacies & Drug Stores
  • 6.5.3. Specialty Pharmacies & Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. GLP-1 Peptides
  • 7.1.2. Somatostatin Analogs
  • 7.1.3. PTH Analogs
  • 7.1.4. GLP-2 Peptides
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 7.2.1. Metabolic Disorders
  • 7.2.2. Endocrine Disorders
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adult
• 7.4. Market Analysis, Insights and Forecast - By Formulation
  • 7.4.1. Tablets
  • 7.4.2. Others
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital Pharmacies
  • 7.5.2. Retail Pharmacies & Drug Stores
  • 7.5.3. Specialty Pharmacies & Others
• 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Italy
  • 7.6.5. Spain
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. GLP-1 Peptides
  • 8.1.2. Somatostatin Analogs
  • 8.1.3. PTH Analogs
  • 8.1.4. GLP-2 Peptides
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 8.2.1. Metabolic Disorders
  • 8.2.2. Endocrine Disorders
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adult
• 8.4. Market Analysis, Insights and Forecast - By Formulation
  • 8.4.1. Tablets
  • 8.4.2. Others
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital Pharmacies
  • 8.5.2. Retail Pharmacies & Drug Stores
  • 8.5.3. Specialty Pharmacies & Others
• 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. GLP-1 Peptides
  • 9.1.2. Somatostatin Analogs
  • 9.1.3. PTH Analogs
  • 9.1.4. GLP-2 Peptides
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 9.2.1. Metabolic Disorders
  • 9.2.2. Endocrine Disorders
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adult
• 9.4. Market Analysis, Insights and Forecast - By Formulation
  • 9.4.1. Tablets
  • 9.4.2. Others
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital Pharmacies
  • 9.5.2. Retail Pharmacies & Drug Stores
  • 9.5.3. Specialty Pharmacies & Others
• 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. GLP-1 Peptides
  • 10.1.2. Somatostatin Analogs
  • 10.1.3. PTH Analogs
  • 10.1.4. GLP-2 Peptides
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Therapeutic Area
  • 10.2.1. Metabolic Disorders
  • 10.2.2. Endocrine Disorders
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adult
• 10.4. Market Analysis, Insights and Forecast - By Formulation
  • 10.4.1. Tablets
  • 10.4.2. Others
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Retail Pharmacies & Drug Stores
  • 10.5.3. Specialty Pharmacies & Others
• 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Novo Nordisk
  • 11.2.2. Chiesi Group
  • 11.2.3. EnteraBio Ltd.
  • 11.2.4. Oramed
  • 11.2.5. Protagonist Therapeutics Inc.
  • 11.2.6. Biocon
  • 11.2.7. Rani Therapeutics